To test this hypothesis, we analyzed a panel of patient-derived neurofibroma or MPNST cells with inactivating NF1, CDKN2A/B, or PRC2 mutations (Supplementary Fig. 5a). The gene discussed is NF1; the disease is neurofibroma.